Kanis, J. A. http://orcid.org/0000-0002-3129-4326
Johansson, H.
Harvey, N. C.
Gudnason, V.
Sigurdsson, G.
Siggeirsdottir, K.
Lorentzon, M.
Liu, E.
Vandenput, L.
McCloskey, E. V.
Article History
Received: 27 August 2020
Accepted: 16 December 2020
First Online: 4 February 2021
Compliance with ethical standards
: The study was approved by the National Bioethics Committee and the Data Protection Authority in Iceland. All participants gave informed written consent.
: V Gudnason, G Sigurdsson, K Siggeirsdottir, E Liu, L Vandenput, and H Johansson have no competing interests to declare.N. Harvey has received consultancy, lecture fees, and honoraria from the Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health, and Internis Pharma.EV McCloskey has received consultancy/lecture fees/grant funding/honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, SanofiAventis, Servier, Synexus, UCB, Viiv, Warner Chilcott, I3 Innovus, and Unilever.JA Kanis is the architect of FRAX® but has no financial interest.M Lorentzon has received lecture fees from Amgen, Lilly, Meda, Renapharma, and UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma and Consilient Health, all outside the presented work